Get the Stockscreener App
289.62
1.11%
-3.26
After Hours:
289.10
-0.52
-0.18%
Insulet Corporation stock is traded at $289.62, with a volume of 1.17M.
It is down -1.11% in the last 24 hours and down -16.38% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$292.88
Open:
$293.75
24h Volume:
1.17M
Relative Volume:
1.76
Market Cap:
$20.37B
Revenue:
$2.36B
Net Income/Loss:
$236.10M
P/E Ratio:
88.14
EPS:
3.286
Net Cash Flow:
$382.50M
1W Performance:
-2.06%
1M Performance:
-16.38%
6M Performance:
-4.03%
1Y Performance:
+12.89%
1-Day Range:
$288.40
$297.01
1-Week Range:
$287.52
$299.22
52-Week Range:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
289.62 | 20.60B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
125.45 | 217.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.61 | 142.48B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.20 | 135.04B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.63 | 126.25B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.66 | 49.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Should Insulet’s (PODD) Expanded Pod Recycling Effort Reframe Its Long‑Term Sustainability Edge? - Yahoo Finance UK
Guidance Update: Can Insulet Corporation (GOV) stock sustain revenue momentum2025 Growth vs Value & Weekly Breakout Watchlists - moha.gov.vn
Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton By Investing.com - Investing.com Nigeria
Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton - Investing.com Nigeria
Returns Recap: Will Insulet Corporation stock outperform value stocksIPO Watch & Risk Controlled Daily Trade Plans - Улправда
Why analysts upgrade Insulet Corporation stockTrade Analysis Summary & Free Accurate Trade Setup Notifications - DonanımHaber
FOMO Trade: Why Insulet Corporation stock attracts high net worth investorsJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - Улправда
Why institutional investors increase stakes in Insulet Corporation (GOV) stockJuly 2025 Intraday Action & Expert Approved Trade Ideas - DonanımHaber
Texas Permanent School Fund Corp Purchases 3,633 Shares of Insulet Corporation $PODD - MarketBeat
Why Insulet Corporation stock attracts global investorsExit Point & Short-Term Swing Trade Alerts - Улправда
Assenagon Asset Management S.A. Raises Stock Position in Insulet Corporation $PODD - MarketBeat
Is Insulet Corporation (GOV) stock positioned for digital growth era2025 Risk Factors & Low Drawdown Investment Ideas - DonanımHaber
Why Insulet Corporation (GOV) stock is a strong analyst pick2025 Biggest Moves & Real-Time Market Sentiment Reports - Улправда
What margin trends mean for Insulet Corporation stockJuly 2025 Technicals & Growth-Oriented Investment Plans - DonanımHaber
Insulet stock price target maintained at $400 by UBS on growth outlook - Investing.com Nigeria
Insulet’s New Omnipod M Study Targets the Untapped Type 2 Diabetes Pump Market - TipRanks
Insulet (PODD) Analyst Rating Update: Truist Securities Lowers P - GuruFocus
Truist Financial Issues Pessimistic Forecast for Insulet (NASDAQ:PODD) Stock Price - MarketBeat
Truist Securities Lowers Price Target on Insulet to $390 From $412, Maintains Buy Rating - marketscreener.com
UBS Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Evercore ISI Upgrades Insulet (NASDAQ:PODD) to "Strong-Buy" - MarketBeat
Insulet stock price target lowered to $203 by BofA Securities - Investing.com
Insulet Corporation (PODD) PT Lowered to $203 at BofA Securities - StreetInsider
Is Insulet stock underperforming the Nasdaq? - MSN
Insulet Corporation (PODD) Announces Amendments to Annual Incentive Plan - GuruFocus
A Look Into Insulet Inc's Price Over Earnings - Sahm
Insulet (PODD): Canaccord Genuity Raises Price Target to $450 | - GuruFocus
Canaccord Genuity Group Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock - MarketBeat
Oak Thistle LLC Acquires New Shares in Insulet Corporation $PODD - MarketBeat
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Evercore ISI Group Initiates Coverage of Insulet (PODD) with Outperform Recommendation - Nasdaq
Insider Sell: Wayne Frederick Sells Shares of Insulet Corp (PODD) - GuruFocus
Insulet Insider Sold Shares Worth $542,510, According to a Recent SEC Filing - marketscreener.com
Evercore ISI initiates Insulet stock with Outperform rating, $370 price target By Investing.com - Investing.com South Africa
Is Insulet Stock Underperforming the Nasdaq? - Barchart.com
Evercore ISI Group Initiates Coverage on Insulet (PODD) with Out - GuruFocus
Evercore ISI initiates Insulet stock with Outperform rating, $370 price target - Investing.com Australia
Evercore ISI Starts Insulet Corporation (PODD) at Outperform, 'Leading the Tubeless Revolution in Insulin Delivery - StreetInsider
Insulet Corp. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Assessing Insulet (PODD) Valuation After Recent Share Price Pullback - Yahoo Finance
Insulet expands pod recycling program to all U.S. customers By Investing.com - Investing.com Nigeria
Insulet Corporation Expands Omnipod®? U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating A More Sustainable Future - marketscreener.com
Insulet expands pod recycling program to all U.S. customers - Investing.com
4 Medical Device Stocks to Buy for Healthy Returns in 2026 - Yahoo Finance Australia
Insulet expands Pod recycling program nationwide across US - StreetInsider
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future - Yahoo Finance
Munro Partners Purchases Shares of 14,355 Insulet Corporation $PODD - MarketBeat
Castleark Management LLC Takes Position in Insulet Corporation $PODD - MarketBeat
Insulet (PODD): Valuation Check After FDA Clearance and Upbeat Earnings Growth Outlook - Sahm
Engineers Gate Manager LP Acquires 96,272 Shares of Insulet Corporation $PODD - MarketBeat
Bellevue Group AG Cuts Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):